The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 22, 2026
Filed:
Sep. 18, 2020
Applicant:
Modernatx, Inc., Cambridge, MA (US);
Inventors:
Kerry E. Benenato, Cambridge, MA (US);
Mark Cornebise, Cambridge, MA (US);
Edward Hennessy, Cambridge, MA (US);
Andrew Mckenzie, Cambridge, MA (US);
Assignee:
ModernaTX, Inc., Cambridge, MA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 9/1272 (2025.01); A61K 31/7105 (2006.01); C07C 237/10 (2006.01); C07C 311/05 (2006.01); C07D 207/456 (2006.01); C07D 209/14 (2006.01); C07D 231/56 (2006.01); C07D 233/88 (2006.01); C07D 237/22 (2006.01); C07D 239/22 (2006.01); C07D 239/38 (2006.01); C07D 241/20 (2006.01); C07D 249/14 (2006.01); C07D 271/08 (2006.01); C07D 285/10 (2006.01); C07D 285/18 (2006.01); C07D 307/68 (2006.01); C07D 319/12 (2006.01); C07F 5/02 (2006.01); C07F 9/36 (2006.01);
U.S. Cl.
CPC ...
A61K 9/1272 (2013.01); A61K 31/7105 (2013.01); C07C 237/10 (2013.01); C07C 311/05 (2013.01); C07D 207/456 (2013.01); C07D 209/14 (2013.01); C07D 231/56 (2013.01); C07D 233/88 (2013.01); C07D 237/22 (2013.01); C07D 239/22 (2013.01); C07D 239/38 (2013.01); C07D 241/20 (2013.01); C07D 249/14 (2013.01); C07D 271/08 (2013.01); C07D 285/10 (2013.01); C07D 285/18 (2013.01); C07D 307/68 (2013.01); C07D 319/12 (2013.01); C07F 5/027 (2013.01); C07F 9/36 (2013.01);
Abstract
The invention features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.